With a more comprehensive antiviral system, we suspect that blocking one of them, the mevalonate/farnesylation/RHOQ pathway, would cause less devastating consequences to the antiviral system in normal cells, in contrast to cancer cells with a weak antiviral system. This evidence concerns the gene RHOQ and cancer.